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Abstract
Numerous studies show that PLD is activated in cells by calcium and by protein kinase C (PKC). We found that human
PLD1 and PLD2 expressed in Sf9 cells can be activated by calcium-mobilizing agonists and by co-expression with PKCK.
The calcium-mobilizing agonists A23187 and CryIC toxin triggered large increases in phosphatidylethanol (PtdEth)
production in Sf9 cells over-expressing PLD1 and PLD2, but not in vector controls. PLD activation by these agonists was
largely dependent on extracellular calcium. Membrane assays demonstrated significant PLD1 and PLD2 activity in the
absence of divalent cations, which could be enhanced by low levels of calcium either in the presence or absence of
magnesium. PLD1 but not PLD2 activity was slightly enhanced by magnesium. Treatment of Sf9 cells expressing PLD1 and
PLD2 with PMA resulted in little PtdEth production. However, a significant and comparable formation of PtdEth occurred
when PLD1 or PLD2 were co-expressed with PKCK, but not PKCN, and was further augmented by PMA. In contrast to
PLD1, co-expressing PLD2 with PKCK or PKCN further enhanced A23187-induced PtdEth production. Immunoprecipita-
tion experiments demonstrated that PLD1 and PLD2 associated with the PKC isoforms in Sf9 cells. Furthermore, in
membrane reconstitution assays, both PLD1 and PLD2 could be stimulated by calmodulin and PKCK-enriched cytosol. The
results indicate that PLD2 as well as PLD1 is subject to agonist-induced activation in intact cells and can be regulated by
calcium and PKC. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The hydrolysis of phosphatidylcholine by phos-
pholipase D is now recognized as an important signal
transduction pathway that is thought to play a role
in functional responses such as secretion, vesicle traf-
¢cking, mitogenesis and NADPH oxidase activation
[1^3]. The product of PLD, phosphatidic acid (PA),
can be converted to diacylglycerol and lysophospha-
tidic acid; however, the role that PA and these lipid
metabolites play in mediating the functional conse-
quences of PLD activation is not understood. PLD
activation occurs in many cell types in response to
agonists, such as hormones, chemotactic peptides,
oxidants, ATP, thrombin, platelet-activating factor,
neurotransmitters, antigen, calcium ionophores, and
phorbol esters [4]. These agonists act through diverse
mechanisms to induce cellular responses suggesting
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that PLD activation can potentially be triggered by
multiple pathways [5,6]. Indeed, numerous signaling
steps have been implicated in PLD activation, such
as an increase in intracellular calcium, and activation
of protein kinase C (PKC), tyrosine kinases and low
molecular weight GTP-binding proteins (G-proteins)
[3].
Two mammalian PLD enzymes PLD1 and PLD2,
have been cloned and shown to have broad tissue
distribution [5,7^9]. Human PLD1 and PLD2 exhibit
51% homology and splice variants have been de-
scribed [8^10]. In vitro characterization of PLD1
and PLD2 has revealed distinct mechanisms of reg-
ulation [5,7,10,11]. Both enzymes prefer phosphatid-
ylcholine as substrate and require phosphatidylino-
sitol 4,5-bisphosphate (PIP2) for activity. However,
PLD1 is activated by PKC and a low molecular
weight G-protein, either from the Rho family or
ADP-ribosylation factor (ARF) [10]. Phosphory-
lation-dependent activation of PLD1 by PKCK has
recently been reported in mammalian cells [12].
PLD1 has also been shown to form a complex with
Ral GTPase which may be important for v-Src-in-
duced PLD activation [13,14]. In contrast, puri¢ed
PLD2 is active in the absence of PKC and the G-
proteins, although it has been shown to be modestly
activated by ARF [9] and oleic acid [15]. It has been
suggested that PLD2 activity may normally be
masked by associated inhibitors, and becomes acti-
vated by derepression when cells are stimulated [5].
Many cells contain both PLD1 and PLD2, but it has
not been established which of these isoforms is re-
sponsible for the PLD activation (phosphatidylalco-
hol production) induced by speci¢c agonists in intact
cells. A recent study has demonstrated that overex-
pressed PLD1 and PLD2 can be activated in cells
with epidermal growth factor [16]. More recently,
PLD2 has been shown to be activated by A23187
in L1210 and P388D1 cells and suggested to be
down stream of cPLA2 activation[6].
We have used the baculovirus expression system in
Sf9 cells as a model to study agonist-induced activa-
tion of speci¢c PLD isoforms. This model is now
being used to study the function of expressed pro-
teins and their role in signal transduction [17^20].
The results demonstrate that both PLD1 and PLD2
are activated by calcium-mobilizing agonists and can
be regulated by PKC.
2. Materials and methods
2.1. Materials
Phosphatidylethanol (PtdEth) and PA were pur-
chased from Avanti Polar Lipids. [9,10-3H]myristic
acid (49.0 Ci/mmol) was from DuPont NEN. Bovine
brain calmodulin and GTPQS were obtained from
CalBiochem. Recombinant baculoviruses containing
PKCK and PKCN were generously supplied by Dr.
Robert Bell (Glaxo Wellcome) and Dr. Susan Jaken
(University of Vermont), respectively. Polyclonal and
monoclonal antibodies for PKCK and PKCN were
purchased from Santa Cruz and Transduction Labo-
ratories, respectively. Puri¢ed N-endotoxin CryIC
from Bacillus thuringiensis was a kind gift from Dr.
Jean-Louis Schwartz, National Research Council,
Montreal, Canada and Dr. Marianne Carey, Case
Western Reserve University, Cleveland, OH. A hu-
man B-cell V phage library was kindly provided by
Dr. Dennis Voelker, National Jewish Medical and
Research Center, Denver, CO.
2.2. Cloning of human PLD2 and PLD1
Two expressed sequence tags (EST) clones
(R69739 and R93485) that exhibited 43^62% homol-
ogy to human PLD1 were used as mixed probes to
screen a human B-cell library (0.6U106 pfu). A 2.1-
kb clone encoding an incomplete coding region, but
containing the 3P-end was obtained. The missing 5P-
coding sequence was generated by rapid ampli¢ca-
tion of cDNA ends (RACE) using total RNA from
HL60 cells. Full-length cDNA was subcloned in pCR
2.1 TA-cloning vector (Promega) that was subse-
quently used for further cloning into di¡erent expres-
sion vectors. PLD1a was cloned by PCR ampli¢ca-
tion from a human spleen cDNA library using
primers 5P-CACGAGGAGCCCTGAGAGTCCGC-
3P (PLD1 sense primer corresponding to nucleotide
positions 3^25), 5P-CAGCCCCCTTTTTACAAGT-
TAGGC-3P (PLD1 antisense primer corresponding
to nucleotide positions 3542^3519). For all PCR am-
pli¢cations, Klen Taq polymerase (Clontech) was
used. DNA sequencing of both strands of PLD1
and PLD2 was carried out using a thermal-sequenase
dye terminator mix (Amersham) and an automated
sequencer (Perkin-Elmer).
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2.3. Culture of Sf9 cells and production of
recombinant baculovirus
Both PLD1 and PLD2 were cloned into pVL 1393
transfer vector (Pharmingen). PLD1 was inserted
into the XbaI and NotI sites, whereas, PLD2 was
cloned into the XbaI site. PLD1 and PLD2 were
also cloned into pAcGHLT (GST-His tag) transfer
vector (Pharmingen) to express as GST and His tag
fusion proteins. Recombinant viruses were generated,
plaque puri¢ed and ampli¢ed by standard protocols
in Sf9 cells. The expression of fusion proteins was
monitored on Western blots using anti-GST mono-
clonal antibody (Santa Cruz), whereas expression of
non-fusion forms was determined by measuring PLD
activity (PtdEth formation) in cell lysates and by
Western blotting using speci¢c antisera for hPLD1
and hPLD2.
2.4. Production of speci¢c antisera against hPLD1
and hPLD2
Fusion proteins corresponding to amino acid se-
quences 12^78 of PLD1 (absent in PLD2) and 7^65
of PLD2 (a region having very low homology to the
PLD1) were generated in bacteria using pGEX 5X
(Pharmacia) expression system. Antiserum was also
raised against full-length GST-PLD1 fusion protein
expressed in Sf9 cells. GST-fusion proteins were pu-
ri¢ed on glutathione agarose beads using standard
protocols. Antibodies were raised in New Zealand
White rabbits. Brie£y, 50^100 Wg GST-fusion pro-
teins in complete Freund’s adjuvant were injected
subcutaneously, followed by booster injections (50
Wg) in incomplete adjuvant every 3^4 weeks. Rabbits
were bled 10^14 days after each booster injection
until maximum titer of antibody was obtained.
2.5. Cell infection and in vivo PLD assay
Sf9 cells were grown and maintained in suspension
in spinner £asks at 27‡C. At the day of infection, Sf9
cells were plated at 0.25U106 cells/well in 24-well
plates in 0.5 ml of TNM-FH medium (Grace’s me-
dium supplemented with 3.3 g yeastolate/l, 3.3 g lac-
talbumin hydrolysate/l, and 1% penicillin/streptomy-
cin/glutamine solution) containing 10% FBS and
were infected with recombinant baculovirus for 1 h.
For certain experiments the e¡ect of co-expressing
PLD1 and PLD2 with PKC isoforms was determined
and compared to expression of PLD1 or PLD2
alone. For these experiments, the multiplicity of in-
fection was kept constant by adjusting with baculo-
virus containing the pVL vector. To keep the total
virus load at a level that does not adversely a¡ect the
Sf9 cells during the experiments, the individual pro-
teins were expressed at sub-maximal levels. After in-
fection, virus-containing medium was replaced with
fresh medium and cells were incubated for 52 h at
27‡C. At 30^32 h post-infection, cells were labeled
with [3H]myristic acid (1.5 WCi/ml) in TNM-FH me-
dium containing 10% FBS and incubated for a fur-
ther 18^20 h. The labeled cells were washed twice
with TNM-FH medium and incubated in the same
medium (containing 1% ethanol) in the presence or
absence of agonist at 27‡C. At the completion of
each incubation, cells were scraped in ice-cold meth-
anol/acetic acid (99:1) and the lipids were extracted
and separated according to Bligh and Dyer as de-
scribed [21].
2.6. Preparation of cytosol and membranes
Sf9 cells were plated in 100-mm dishes (7U106
cells), infected with recombinant virus (PLD1 or
PLD2) and labeled with [3H]myristic acid (1.5 WCi/
ml) as described above. At 52 h post infection, cells
were washed twice with ice-cold bu¡er A (25 mM
HEPES pH 7.2, 125 mM NaCl, 2.5 mM KCl, 0.7
mM MgCl2, 0.5 mM EGTA, 10 mM glucose). Cells
were scraped in bu¡er B (50 mM HEPES pH 7.2,
100 mM KCl, 5 mM NaCl, 1 mM EGTA, 1 mM
PMSF, 1.5 WM aprotinin, 21 WM leupeptin, 14.5 WM
pepstatin A, 64 WM benzamidine HCl and 0.5 mM
phenanthroline) unless otherwise indicated, and the
cell suspension (1.4U107/ml) sonicated at 4‡C (twice
for 20 s) using a probe sonicator. Membranes and
cytosol were obtained by centrifugation at
125 000Ug for 1 h.
2.7. In vitro PLD assay
[3H]Myristic acid labeled membranes prepared
from Sf9 cells expressing PLD1 or PLD2 were as-
sayed for PLD activity as previously described [22].
Brie£y, the membranes (5U105 dpm/50 Wg protein)
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were incubated for 30 min in a 60-Wl volume in bu¡er
B containing 1% ethanol and di¡erent agonists as
indicated in the ¢gures. The concentration of free
calcium in assays was maintained by Ca2/EGTA
bu¡ers and was 1.5 WM unless otherwise indicated.
The reactions were halted by the addition of 375 Wl
chloroform/methanol/HCl (50:98:2) and the lipids
were extracted and analyzed for [3H]PtdEth forma-
tion as described [21].
2.8. SDS^polyacrylamide gel electrophoresis, Western
blot analysis and immunoprecipitation
For the analysis of PLD1 and PLD2, 4 M urea
was included in the SDS^polyacrylamide gel (7.5%)
and the Laemmli sample bu¡er. Samples were not
boiled prior to electrophoresis. Proteins were electro-
phoretically transferred onto nitrocellulose mem-
brane and blocked in Tris-bu¡ered saline containing
5% non-fat milk and 0.05% Tween 20. Western blot
analysis using speci¢c antibodies was performed us-
ing the Amersham ECL system. For immunoprecipi-
tation, Sf9 cells infected with recombinant baculovir-
us(s) in 12-well plates (0.5U106 cell/well) were
washed twice with ice-cold phosphate-bu¡ered saline
and lysed in 0.3 ml lysis bu¡er (50 mM HEPES pH
7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 10% glycerol, 1 mM PMSF, 1.5 WM
aprotinin, 21 WM leupeptin, 14.5 WM pepstatin A, 64
WM benzamidine HCl and 0.5 mM phenanthroline)
on ice for 15 min. After lysis, insoluble material was
removed by centrifugation at 15 000Ug for 10 min.
The supernatant (250 Wg) was incubated in a rotator
for 1 h at 4‡C with pre-immune serum (1:50 dilution)
and 50 Wl of protein A-Sepharose that was prepared
in lysis bu¡er. The pre-cleared material was centri-
fuged and the resulting supernatant was incubated
with the speci¢c antibody for 1 h in a rotator, fol-
lowed by an additional 30 min incubation with 50 Wl
of protein A-Sepharose. The precipitates were then
washed four times with lysis bu¡er and were ¢nally
resuspended in 2ULaemmli bu¡er for further analy-
sis.
3. Results
Sf9 cells were used as a model to compare the
activation of PLD1 and PLD2. Sf9 cells have a sim-
ilar phospholipid pro¢le as mammalian cells and we
have found that they exhibit similar mechanisms for
cytosolic phospholipase A2 (cPLA2) activation as
mammalian cells [20,23]. The baculovirus expression
system using Sf9 insect cells proved to be a useful
model for studying the mechanism of activation of
individual isoforms in intact cells. This system has
successfully been used for studying the regulation
of a variety of mammalian enzymes such as cPLA2
and receptors including thrombin and M5 muscarinic
receptors [20,24^26]. Western blot analysis of lysates
from Sf9 cells expressing PLD1 or PLD2 revealed
proteins at 120 and 97 kDa, respectively. No immu-
noreactive material was evident using these antibod-
ies in lysates from vector control cells (data not
shown). In many cell systems, PLD activation can
be triggered by an increase in intracellular calcium.
However, the PLD isoform that is activated in cells
by calcium has not been identi¢ed. To investigate
this, [3H]myristic acid-labeled Sf9 cells expressing ei-
ther PLD1 or PLD2 were treated with A23187 in the
presence of ethanol and the production of
[3H]PtdEth was measured (Fig. 1). The basal level
of PtdEth production in Sf9 cells not expressing
PLD (vector control) was very low, but it did in-
crease slightly in response to A23187. This probably
Fig. 1. Activation of PLD1 and PLD2 by A23187. Sf9 cells
were infected with recombinant viruses for the expression of the
indicated proteins or with recombinant virus containing vector
alone (pVL). [3H]Myristic acid-labeled cells were then incubated
in the absence (US, unstimulated) or presence of A23187 (2 Wg/
ml) in 1% ethanol for 30 min. The total cellular lipids were ex-
tracted and analyzed for the [3H]PtdEth production. The results
are expressed as the mean þ S.E. of three independent experi-
ments.
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re£ects the presence of endogenous PLD in Sf9 cells
as observed by others [9]. Overexpressing PLD1 and
PLD2 slightly enhanced the basal level of PtdEth
production in unstimulated Sf9 cells. Noticeably,
basal PLD2 activity was low, and comparable to
PLD1 in Sf9 cells, unlike other previous studies in
which mouse rPLD2 and human rPLD2 exhibited
higher basal activity when over-expressed in COS
cells, [5,6]. Treatment with A23187 induced a large
increase in PtdEth production in Sf9 cells over-ex-
pressing PLD1 or PLD2.
An agonist speci¢c for insect cells, CryIC toxin
from B. thuringiensis, was also used to investigate a
role for calcium in regulation of the PLD enzymes.
The crystal (Cry) protein toxins are inclusions
formed by the Gram-positive soil bacterium during
sporulation. CryIC toxin has been shown to induce a
sustained increase in intracellular calcium in Sf9 cells,
and is thought to act by a receptor-mediated process
[27^29]. In previous work, we have shown that it
activates cPLA2 expressed in Sf9 cells [20]. As shown
in Fig. 2, CryIC toxin induced a concentration-de-
pendent increase in [3H]PtdEth production in Sf9
cells expressing either PLD1 or PLD2. CryIC toxin
at 2 Wg/ml had only a minimal e¡ect (1.5-fold in-
crease) on PtdEth production from vector control
cells (not shown). The activation of PLD1 by CryIC
toxin was entirely dependent on the presence of ex-
tracellular calcium (Fig. 3). We have previously re-
ported that incubating Sf9 cells in medium contain-
ing decreasing amounts of calcium results in
decreased levels of intracellular calcium mobilized
by CryIC toxin [20]. The activation of PLD2 by
the toxin was also dependent on extracellular calci-
um; however, a small but signi¢cant activation of
PLD2 occurred in medium containing EGTA. The
Fig. 2. Activation of PLD1 and PLD2 by CryIC toxin. Cells
were infected with recombinant virus for PLD1 and PLD2.
Cells labeled with [3H]myristic acid were stimulated in the ab-
sence (US, unstimulated) or presence of the indicated concen-
trations of CryIC toxin in 1% ethanol for 30 min. The total cel-
lular lipids were extracted and analyzed for [3H]PtdEth
production. The results are expressed as the mean þ S.D. of
triplicate samples from a representative experiment and the
data were con¢rmed in three experiments.
Fig. 3. E¡ect of extracellular calcium on the activation of
PLD1 and PLD2 by CrylC toxin. [3H]Myristic acid-labeled Sf9
cells expressing either PLD1 (A) or PLD2 (B) were incubated
in calcium free incomplete Grace’s medium containing the indi-
cated amount of EGTA or calcium chloride. Cells were stimu-
lated with CryIC toxin (2 Wg/ml) and incubated for 30 min in
the presence of 1% ethanol. The total cellular lipids were ex-
tracted and analyzed for [3H]PtdEth production. The results are
expressed as the mean þ S.D. of triplicate samples from a repre-
sentative experiment. Three independent experiments were car-
ried out to con¢rm the data.
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level of intracellular calcium in unstimulated and
CryIC-treated Sf9 cells incubated in medium contain-
ing EGTA is below the level of detection (6 5 nM)
[20]. This suggests that other events induced by the
toxin also play a role in the activation of PLD2.
When expressed in Sf9 cells, PLD1 and PLD2 were
primarily localized in the particulate (membrane)
fraction of Sf9 cells when analyzed on Western blots
(Fig. 4). Approximately 20^30% of the total cellular
PLD1 or PLD2 was in the soluble fraction. A similar
distribution was obtained when the cells were ho-
mogenized either in bu¡er containing EGTA or cal-
cium (not shown). Experiments were carried out to
determine the e¡ect of calcium on enzyme activity of
PLD1 and PLD2 in vitro. For these assays, mem-
branes from [3H]myristic acid-labeled Sf9 cells ex-
pressing either PLD1 or PLD2 were used. The ad-
vantage of this assay is that the enzyme is in a
biologically relevant environment acting on endoge-
nous substrate and is in the presence of physiologi-
cally relevant concentrations of the phospholipid ac-
tivator PIP2. The e¡ect of calcium concentration on
PLD activity was evaluated both in the presence and
absence of magnesium. Both PLD isoforms exhibited
enzymatic activity in the absence of divalent cations
and activity was further enhanced by calcium (Fig.
5). PLD1 activity increased up to 1 WM calcium after
which activity plateaued. The presence of magnesium
slightly enhanced PLD1 activity in the membranes
when assayed either with or without calcium. PLD2
exhibited increased activity at 0.1 WM calcium, but
was not increased further with higher concentrations.
Fig. 4. Distribution of PLD1 and PLD2 in soluble and mem-
brane fractions of Sf9 cells. Sf9 cells were infected with re-
combinant viruses for 52 h. Membrane (M) was resuspended in
bu¡er A in a volume that was equivalent to the total volume
of cytosol (C). Equal volumes of cytosol (4 Wg protein) and
membrane fractions (2 Wg protein) were subjected to urea/SDS^
PAGE and immunoblotted for PLD1 and PLD2. A representa-
tive experiment is shown and data were con¢rmed in three in-
dependent experiments.
Fig. 5. E¡ect of calcium concentration on PLD1 and PLD2 ac-
tivities in Sf9 membranes. Membranes were prepared from
[3H]myristic acid-labeled Sf9 cells expressing either PLD1 (A)
or PLD2 (B). Membrane fractions (5U105 dpm/assay) were in-
cubated in bu¡ers containing the indicated concentrations of
free calcium either with or without 5 mM MgCl2. Total incuba-
tion volume for each assay was 60 Wl. After 30 min incubation
in the presence of 1% ethanol, the total lipids were extracted
and analyzed for [3H]PtdEth production. The results are ex-
pressed as the mean þ S.D. of triplicate samples from a repre-
sentative experiment. Two independent experiments gave similar
results.
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Magnesium had no e¡ect on PLD2 activity. Control
membranes prepared from cells infected with virus
containing empty vector did not exhibit signi¢cant
PLD activity.
PKC has been shown to activate PLD1 but not
PLD2 activity in vitro [5,7,10]. However, the e¡ect
of PKC on PLD2 activation in intact cells has not
been investigated. The e¡ect of co-expressing PLD
with PKCK and PKCN on PLD activation in re-
sponse to A23187 and PMA was evaluated in Sf9
cells labeled with [3H]myristic acid (Fig. 6). In Sf9
cells expressing only PLD1 or PLD2, PMA only
weakly stimulated PtdEth production (by approxi-
mately 50%) in contrast to the large activation ob-
served with A23187. The response to A23187 was not
augmented by PMA. When PLD1 and PLD2 were
co-expressed with PKCK there was a signi¢cant in-
crease in PtdEth production in unstimulated cells
and further activation of both PLD isoforms oc-
curred in response to PMA. This e¡ect was not sig-
ni¢cant when the PLD isoforms were co-expressed
with PKCN. Co-expressing PLD1 with either PKCK
or PKCN did not further in£uence PtdEth production
in response to A23187 or A23187 plus PMA com-
pared to cells expressing PLD1 alone. However, co-
expressing the PKC isoforms with PLD2 augmented
A23187-induced PtdEth formation compared to cells
expressing PLD2 alone.
PLD1 has previously been shown to associate with
PKCK in intact cells [30,31]. Since PLD2 could be
activated by co-expression with PKCK experiments
were carried out to determine if it also associated
with PKC in cells. PLD1 and PLD2 were expressed
alone or with either PKCK or PKCN in Sf9 cells.
Immunoprecipitation of PKCK and PKCN from Sf9
cells over-expressing the PLD isoforms, but not over-
expressing the PKC isoforms co-immunoprecipitated
PLD1 and to a lesser extent PLD2 (Fig. 7). This
suggests that the PLD isoforms associate with endog-
enous Sf9 cell PKC isoforms as previously shown for
PLD1 [31]. Endogenous immunoreactive proteins are
weakly detected in Sf9 cells lysates at 72 kDa using
the anti-PKCK antibody and 74 kDa for the anti-
PKCN antibody (not shown). When the PKC and
PLD isoforms were co-expressed in Sf9 cells, a small
increase in PLD1 and a larger increase of PLD2 was
recovered in the PKCK and PKCN immunoprecipi-
tates. The amount of PLD1 and PLD2 recovered in
PKCK immunoprecipitates was slightly enhanced by
treating the Sf9 cells with PMA. The recovery of
PLD isoforms in anti-PKCN immunoprecipitates
was una¡ected by PMA treatment.
Additional in vitro membrane assays were carried
Fig. 6. E¡ect of expression of PKCK or PKCN on PLD1 and
PLD2 activation by PMA and A23187. Sf9 cells were infected
with recombinant viruses for expression of (A) PLD1 with and
without PKCs or (B) PLD2 with and without PKCs. The total
multiplicity of infection was kept constant by adjusting with re-
combinant virus containing the transfer vector pVL1393. Cells
were labeled with [3H]myristic acid and then stimulated with
DMSO (US, unstimulated), PMA (250 nM), A23187 (2 Wg/ml)
or PMA (250 nM) plus A23187 (2 Wg/ml) in the presence of 1%
ethanol for 30 min. The total cellular lipids were extracted and
analyzed for [3H]PtdEth production. Sf9 cells infected with ba-
culovirus containing only the vector were labeled with
[3H]myristic acid and incubated with and without the agonists
to obtain background counts. These were approximately 500
dpm and were subtracted from the corresponding experimental
counts. The results are expressed as the mean þ S.E. of three in-
dependent experiments. [3H]PtdEth production is shown as per-
centage of control (600 dpm for PLD1 and 325 dpm for
PLD2).
BBAMCR 14636 22-5-00
A.R. Siddiqi et al. / Biochimica et Biophysica Acta 1497 (2000) 103^114 109
out to investigate the role of calcium and PKC in
regulating PLD1 and PLD2 activity. Both PLD iso-
forms exhibited signi¢cant activity when assayed in
vitro in the absence of calcium and were near max-
imally active at levels of calcium found in resting
cells. This suggested that PLD activation triggered
by an increase in intracellular calcium in cells is
not simply due to a cofactor requirement for calcium
for catalysis. A role for calmodulin in the regulation
of PLD activation in intact cells has been implicated
[32^34], and the e¡ect of this calcium binding protein
on PLD activity in membranes was investigated. In
addition, the e¡ect of PKCK and GTPQS on PLD
activity was evaluated. Membranes from [3H]myristic
acid-labeled Sf9 cells expressing either PLD1 or
PLD2 were isolated and PtdEth formation was meas-
ured in the presence of calcium and magnesium-ATP
(Table 1). Mg-ATP was included in order to prevent
a possible decline in the PIP2 pool during in vitro
incubation. The e¡ect of PKCK was evaluated by
using cytosol from Sf9 cells over-expressing PKCK
compared to cytosol from Sf9 cells not expressing
the kinase. Both PLD1 and PLD2 activity was en-
hanced approximately 2-fold by cytosol containing
PKCK, whereas, cytosol from Sf9 cells not expressing
PKCK was less e¡ective. The addition of calmodulin
increased PLD1 activity by almost 2-fold and was
slightly more e¡ective on PLD2 (2.5-fold). Activation
Fig. 7. Co-immunoprecipitation of PLDs with PKCK or PKCN. Sf9 cells expressing PLD1 (A) or PLD2 (B) alone or co-expressed
with the PKC isoforms were activated with PMA (250 nM) for 5 min. Cell lysates were prepared, equalized for protein (250 Wg) and
immunoprecipitated using monoclonal anti-PKCK or anti-PKCN. Samples obtained from the PKC immunoprecipitations were ana-
lyzed for PLD or PKC isoforms on Western blots. Whole cell lysates (2 Wg protein) were also analyzed for PLD or PKC isoforms on
Western blots to evaluate expression levels. A representative experiment is shown and the results were con¢rmed in three independent
experiments.
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of both PLD1 and PLD2 by calmodulin was calcium
dependent as no signi¢cant e¡ect was observed in the
presence of excess EGTA (data not shown). The ad-
dition of PKCK-containing cytosol together with cal-
modulin further enhanced activity of PLD1 and
PLD2. The greatest increase in PLD1 and PLD2
activity (3-fold and 3.5-fold, respectively) occurred
in the presence of PKCK-enriched cytosol, calmodu-
lin and GTPQS. PMA had no stimulatory e¡ect on
both PLD1 and PLD2 activity in the presence or
absence of PKCK-enriched cytosol (data not shown).
The PLD activity measured in the membrane frac-
tion was due to the overexpressed isoforms since ac-
tivity in membranes from cells infected with virus
containing only the vector was not above back-
ground levels and was not increased by any of the
added factors.
4. Discussion
PLD isoforms are present at low levels in cells and
are not readily detectable with available antibodies.
In addition, many cells express both PLD1 and
PLD2 [35], consequently, little is known about the
regulation of individual endogenous PLD isoforms.
Sf9 cells were a useful model for comparing the reg-
ulation of the PLD isoforms by calcium and PKC.
The PLD enzymes are primarily associated with the
membrane fraction in Sf9 cells, but signi¢cant
amounts are present in the cytosol as previously re-
ported for PLD1 and PLD2 over-expressed in Sf9
cells and COS cells [7,9,11]. The presence of cytosolic
PLD in mammalian cells has also been described;
however, the speci¢c isoform has not been identi¢ed
[21,36]. Over-expression of mouse or human PLD2 in
COS and HEK293 cells has been reported to result
in spontaneous high level of phosphatidylbutanol
production, in contrast to over-expression of PLD1
[5,6,16]. This is consistent with studies showing that
puri¢ed mouse PLD2 exhibits high constitutive activ-
ity when assayed using exogenous phospholipid
vesicles as substrate [5]. However in the Sf9 model,
over-expression of PLD1 and PLD2 resulted in only
a small increase in basal phosphatidylethanol pro-
duction. This could be due to di¡erences in the level
of endogenous regulators or inhibitors present in Sf9
cells compared to the mammalian cell models. In
addition, using membranes from Sf9 cells to assay
the PLD isoforms with endogenous substrate, we
¢nd that the basal activity of PLD2 is comparable
to the basal PLD1 activity. Lopez et al. [9] also re-
ported comparable basal activities of membrane as-
sociated PLD1 and PLD2 from Sf9 cells using exog-
enous vesicles as substrate, and suggested that the
di¡erence between puri¢ed and membrane associated
PLD2 may be due to removal of inhibitory factors
during puri¢cation of the enzyme [9].
PLD1 and PLD2 expressed in Sf9 cells exhibited
surprising similarities in their ability to be activated
by calcium-mobilizing agonists. The activation of
PLD1 and PLD2 occurred with agonists that induce
a sustained increase in intracellular calcium, and the
response was largely dependent on an in£ux of ex-
tracellular calcium. There are numerous reports of
PLD activation by calcium in diverse cell models.
Calcium ionophores can activate PLD, and stimula-
tion of PLD through certain G-protein-coupled re-
ceptors has been shown to require extracellular cal-
cium [37]. However, it has not been clear whether
Table 1
E¡ect of PKCK and calmodulin on PLD isoforms in Sf9 mem-
branes
Additions PLD1 (%) PLD2 (%)
None 100 100
Cytosol (control) 134 þ 6.60 148 þ 5.60
Cytosol (PKCK) 173 þ 7.60 180 þ 28.9
CaM 188 þ 14.4 256 þ 33.4
CaM+cytosol (control) 220 þ 29.7 271 þ 32.2
CaM+cytosol (PKCK) 255 þ 31.6 316 þ 23.4
CaM+cytosol (control)+GTPQS 297 þ 24.4 312 þ 11.9
CaM+cytosol (PKCK)+GTPQS 320 þ 40.5 349 þ 7.37
Membranes were prepared from [3H]myristic acid-labeled cells
expressing either PLD1 or PLD2 in the presence of 2 WM free
calcium and 1 mM MgCl2. As shown, membranes (50 Wg) were
reconstituted with cytosol (25 Wg) obtained either from control
Sf9 cells infected with virus containing empty vector (cytosol
(control)) or from Sf9 cells over-expressing PKCK (cytosol
(PKCK)), or calmodulin (CaM) (1.5 WM) or GTPQS (50 WM).
Incubations were carried out in a total volume of 60 Wl for 30
min at 37‡C in assay bu¡er containing 5 mM MgCl2, 2 WM
free Ca2, 100 WM Mg-ATP and 1% ethanol. For background
control, membranes were incubated on ice. Total cellular lipids
were extracted and analyzed for [3H]PtdEth production. Back-
ground control counts (700 dpm for PLD1 and 1100 dpm for
PLD2) were subtracted from the experimental counts. The re-
sults are expressed as the mean þ S.E. of three independent ex-
periments.
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calcium is acting directly to activate PLD or indi-
rectly through an unknown signaling mechanism. Pu-
ri¢ed recombinant PLD1 has been shown to require
magnesium, but to be insensitive to calcium when
assayed in the presence of magnesium [10]. Puri¢ed
recombinant rat brain PLD1 exhibits low activity in
the absence of divalent cations, but is stimulated to
similar extents by magnesium or calcium [31]. These
data suggest that at physiological magnesium con-
centrations, calcium does not directly activate
PLD1. When assayed in membranes from Sf9 cells,
PLD1 and PLD2 exhibited signi¢cant activity in the
absence of divalent cations. However, low levels of
calcium stimulated activity even in the presence of
magnesium. It is possible that the stimulation of
PLD by calcium may be due to some unknown fac-
tors, perhaps calcium-binding proteins, in the mem-
brane that mediate the e¡ect. Our results suggest that
calmodulin may play a role in activation of PLD1
and PLD2. Previous work has shown that PLD acti-
vation in rabbit peritoneal neutrophils by A23187
and FMLP is suppressed by inhibitors of calmodulin
and myosin light chain kinase [32,33]. Calmodulin
antagonists have also been shown to inhibit anti-
gen-stimulated PLD activation in RBL-2H3 cells
[34]. Although the isoform of PLD involved is not
known, these studies indicate that PLD can be regu-
lated by calcium through an indirect mechanism in-
volving calmodulin.
There are numerous studies showing PKC-depen-
dent activation of PLD in intact cells [5,10,37] and in
light of previous reports of stimulation of PLD1, but
not PLD2, by PKC in vitro it seemed likely that
PLD1 was the isoform regulated by PKC. However,
our results suggest that PLD2 may also be regulated
by PKC in intact cells. Both PLD1 and PLD2 asso-
ciate with and are activated by PKCK in Sf9 cells.
The activation and association does not require but
is augmented by treating the cells with PMA. A strict
requirement for PMA for the activation and associ-
ation of PLD1 by PKCK has been reported [30].
However, our results and other studies have not
shown a strict requirement for PMA for the activa-
tion of PLD1 by PKCK, although PMA further en-
hances the activation in intact cells as we observed
[10,31,38]. The activation of PLD1 by PKCK has
been shown to be mediated by the regulatory domain
of PKC and to be independent of its kinase activity
[38]. It has recently been shown that the N-terminus
of PLD1 is required for the activation by and asso-
ciation with PKCK, although an additional region of
PLD1 is also implicated [31,39]. Recent work has
con¢rmed that direct stimulation of PLD1 by PKC
is essential for PLD1 activation through G-protein-
coupled receptor signaling [40]. Like PLD1, PLD2
was also activated in a similar fashion by PKCK
when co-expressed in Sf9 cells. Over-expression of
mouse PLD2 in COS cells has previously been shown
to be modestly activated by PMA (2-fold) whereas
PLD1 activation by PMA is much greater (10^15-
fold) [5]. Similar results were observed with human
PLD1 and PLD2 over-expressed in HEK cells [6].
However, in both these models, there was high basal
activity from over-expressing PLD2 which may par-
tially mask a PMA stimulatory e¡ect. The ability to
demonstrate PLD2 activation by PKC in Sf9 cells
may be due to the combination of the low basal
activity of PLD2 in Sf9 cells and co-expression
with PKCK which has not previously been investi-
gated. PLD2 activation was enhanced in response
to calcium ionophore when it was co-expressed
with PKCK or PKCN. The mechanism for this is
not known but since PKCN is not regulated by cal-
cium, the results suggest that it is only able to exert
an e¡ect once PLD2 is partially activated or modi¢ed
by the calcium-induced signals. The lack of e¡ect of
co-expression with PKCN on PLD1 activation is con-
sistent with previous reports showing that this iso-
form does not activate PLD1 in vitro [31].
When assayed in vitro using membranes of Sf9
cells, PLD1 and PLD2 activity could be detected in
the absence of added cofactors suggesting the pres-
ence of endogenous activators. PIP2 is necessary for
PLD activity and would be expected to be present in
the membrane. Using the in vitro membrane assay,
PLD1 and PLD2 were modestly enhanced to a sim-
ilar extent by PKCK-enriched cytosol. Previous stud-
ies have reported a greater degree of activation in
vitro of PLD1 by PKCK and no activation of
PLD2 [10,31]. However, these studies used an exog-
enous lipid vesicle assay in which the molar ratio of
PIP2 is very high. Using this vesicle assay, it has been
shown that PLD2 activity is exceedingly high and it
is possible that this masks any e¡ect of potential
regulators [5]. The vesicle assay has also shown
that PKC activates PLD1 synergistically with PIP2
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and low molecular weight G-proteins. Therefore, the
modest activation of PLD1 by PKCK containing cy-
tosol could be explained by the low, physiological
level of PIP2 that would be in the membrane and
the probable lack of activated low molecular weight
G-proteins. The addition of GTPQS to the in vitro
membrane assay only weakly stimulated PLD1 activ-
ity consistent with a lack of the G-proteins.
The regulation of PLD isoforms is a complex pro-
cess involving multiple mechanisms. In addition,
there may be di¡erences in the regulation when eval-
uated in vitro compared to intact cells. Our experi-
ments over-expressing PLD2 with PKC in Sf9 cells
together with the in vitro data, suggests there may be
a functional interaction and regulation of PLD2 by
PKC. Calcium also plays a role in activation of
PLD1 and PLD2 through some calcium-dependent
signaling pathway that may involve calmodulin or
other calcium binding proteins.
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